Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.52 |
| ▸ | MMP3 | P08254 | 3/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 17/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | MMP25 | Q9NPA2 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691573 | 0.92 | MMP9 (0.61) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3678177 | 0.90 | MMP9 (0.48) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL14822934 | 0.88 | MMP2 (0.55) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3676623 | 0.86 | MMP9 (0.63) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL13409993 | 0.85 | MMP2 (0.52) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL14823005 | 0.80 | MMP9 (0.65) | MMP2MMP3MMP13MMP9MMP1 | |
| Trifluoroacetic Acid SCHEMBL3690765 | 0.79 | MMP2 (0.47) | MMP2MMP3MMP13MMP9MMP1 | |
| Trifluoroacetic Acid SCHEMBL3690770 | 0.79 | MMP2 (0.47) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3676461 | 0.78 | SMN1; SMN2 (0.48) | MMP2MMP9 | |
| SCHEMBL14822950 | 0.78 | MMP9 (0.50) | MMP2MMP3MMP13MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | MMP2 961/4885MMP3 958/4885MMP13 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.